Japan’s Sysmex Corp said on Thursday it has received regulatory approval in Japan for a blood test to detect amyloid beta in the brain, a hallmark of Alzheimer’s disease.
The company developed the test with Japanese drugmaker Eisai Co and received approval from regulators on December 19, the company said in a statement.
The test kit uses a small amount of a patient’s blood to measure amyloid beta accumulation in the brain, allowing for earlier diagnosis and treatment.